Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label KER-047 study in adults with IRIDA
NL-OMON54150Phase 2Recruiting
- Sponsor
- Keros Therapeutics
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KER-047 in iron deficiency anemia (IDA), sponsored by Keros Therapeutics. Primary endpoint: Safety and tolerability. Started Feb 2022; status: recruiting.
02
Drugs
KER-047
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NL-OMON54150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54150.